Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Bonella

Showing results (141-150 of 169) with videos related to

Pageof 17
Sort By:
Respirology (Carlton, Vic.)|June 2, 2022
Genetic testing in interstitial lung disease: An international surveyMichelle Terwiel, Raphael Borie, Bruno Crestani, et al.
American Journal of Respiratory and Critical Care Medicine|March 14, 2024
Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary FibrosisWaldo L L D Mattos, Nasreen Khalil, Lisa G Spencer, et al.
The European Respiratory Journal|August 15, 2024
European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosisCormac McCarthy, Francesco Bonella, Marissa O'Callaghan, et al.
The New England Journal of Medicine|August 20, 2025
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar ProteinosisBruce C Trapnell, Yoshikazu Inoue, Francesco Bonella, et al.
The European Respiratory Journal|June 18, 2021
ERS clinical practice guidelines on treatment of sarcoidosisRobert P Baughman, Dominique Valeyre, Peter Korsten, et al.
The Lancet. Respiratory Medicine|April 2, 2021
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialJürgen Behr, Antje Prasse, Michael Kreuter, et al.
Rheumatology (Oxford, England)|January 28, 2023
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic SclerosisMichael Kreuter, Francesco Bonella, Norbert Blank, et al.
Clinical and Experimental Rheumatology|February 28, 2022
Defining anti-synthetase syndrome: a systematic literature reviewGiovanni Zanframundo, Sara Faghihi-Kashani, Carlo Alberto Scirè, et al.
Chest|August 15, 2023
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic SclerosisPia Moinzadeh, Francesco Bonella, Max Oberste, et al.
Respirology (Carlton, Vic.)|September 18, 2022
Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in EuropeTheodoros Karampitsakos, Paolo Spagnolo, Nesrin Mogulkoc, et al.
Pageof 17

Showing results (141-150 of 169) with videos related to

Sort By:
Pageof 17
Respirology (Carlton, Vic.)|June 2, 2022
Genetic testing in interstitial lung disease: An international surveyMichelle Terwiel, Raphael Borie, Bruno Crestani, et al.
American Journal of Respiratory and Critical Care Medicine|March 14, 2024
Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary FibrosisWaldo L L D Mattos, Nasreen Khalil, Lisa G Spencer, et al.
The European Respiratory Journal|August 15, 2024
European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosisCormac McCarthy, Francesco Bonella, Marissa O'Callaghan, et al.
The New England Journal of Medicine|August 20, 2025
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar ProteinosisBruce C Trapnell, Yoshikazu Inoue, Francesco Bonella, et al.
The European Respiratory Journal|June 18, 2021
ERS clinical practice guidelines on treatment of sarcoidosisRobert P Baughman, Dominique Valeyre, Peter Korsten, et al.
The Lancet. Respiratory Medicine|April 2, 2021
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialJürgen Behr, Antje Prasse, Michael Kreuter, et al.
Rheumatology (Oxford, England)|January 28, 2023
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic SclerosisMichael Kreuter, Francesco Bonella, Norbert Blank, et al.
Clinical and Experimental Rheumatology|February 28, 2022
Defining anti-synthetase syndrome: a systematic literature reviewGiovanni Zanframundo, Sara Faghihi-Kashani, Carlo Alberto Scirè, et al.
Chest|August 15, 2023
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic SclerosisPia Moinzadeh, Francesco Bonella, Max Oberste, et al.
Respirology (Carlton, Vic.)|September 18, 2022
Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in EuropeTheodoros Karampitsakos, Paolo Spagnolo, Nesrin Mogulkoc, et al.
Pageof 17